Legal Opinion
Mylan Pharmaceuticals Inc. v. Research Corporation Tech.
Court of Appeals for the Federal Circuit
Decided February 1, 2019No. 2017-2088, 2017-2089, 2017-2091PublishedCited by 6 opinions
1Opinion of the Court
Lourie, Circuit Judge.
*1368 Mylan Pharmaceuticals Inc. ("Mylan"), Breckenridge Pharmaceutical, Inc. ("Breckenridge"), and Alembic Pharmaceuticals, Ltd. ("Alembic") (collectively, "Appellants") appeal from the final written decision of the U.S. Patent and Trademark Office Patent Trial and Appeal Board ("the Board") in an inter partes review concluding that claims 1-13 of U.S. Reissue Patent 38,551 ("the '551 patent") are not unpatentable. See Argentum Pharm. LLC v. Research Corp. Techs., IPR 2016-00204, 2017 WL 1096590 , at *1-2 (P.T.A.B. Mar. 22, 2017) (" Decision "). For the reasons detailed below,…
2Cases cited16 opinions
- Consolidated Edison Co. v. National Labor Relations BoardSupreme Court of the United States · 1938
- Allen v. WrightSupreme Court of the United States · 1984
- Lexmark Int'l, Inc. v. Static Control Components, Inc.Supreme Court of the United States · 2014
- Davis v. Michigan Department of the TreasurySupreme Court of the United States · 1989
- In Re Robert J. Gartside and Richard C. NortonCourt of Appeals for the Federal Circuit · 2000
11 more not listed; retrieve them via the Exa API.
3Cited by6 opinions
- Intuitive Surgical, Inc. v. Ethicon LLCCourt of Appeals for the Federal Circuit · 2022
- Mayne Pharma International Pty v. Merck Sharp & Dohme Corp.Court of Appeals for the Federal Circuit · 2019
- Fitbit, Inc. v. Valencell, Inc.Court of Appeals for the Federal Circuit · 2020
- Intuitive Surgical, Inc. v. Ethicon LLCCourt of Appeals for the Federal Circuit · 2022
- Palo Alto Networks, Inc. v. Finjan, Inc.Court of Appeals for the Federal Circuit · 2019
1 more not listed; retrieve them via the Exa API.